Fig. 7

CEAMB NPs can effectively silence drug-resistance genes in 510K cells and then cause changes in cell viability, cycle, and apoptosis. 510 K cells were incubated with the control PBS and different NPs: CHCE/Adriamycin nanoparticles (CEA NPs), CHCE/Adriamycin/MVP-siRNA nanoparticles (CEAM NPs), CHCE/Adriamycin/BCL2- siRNA nanoparticles (CEAB NPs), and CHCE/Adriamycin/MVP-siRNA /BCL2-siRNA nanoparticles (CEAMB NPs). Next, the mRNA levels of MVP and bcl2 were detected by RT-qPCR respectively (A, B). (mean ± sem, n = 3). *p < 0.05, double-tailed t-test. Also, the protein of treated cells was extracted, and the expression levels of MPV and BCL2 was detected by western blot (C, D). In the above, the mRNA and protein levels of housekeeping gene GAPDH were used as normalization internal control (E). MTS assay was used to detect the viability ratio of 510 K cells compared with the PBS treated group (mean ± sem, n = 3). NS: no significant difference. *p < 0.05, **p < 0.01, double-tailed t-test. In all groups above, the cell cycle (F, G) and apoptosis (H) of 510K cells were detected by flow cytometry. The lower left quadrant, lower right quadrant, upper right quadrant, and upper left quadrant represented the survival, early apoptosis, late apoptosis, and necrosis, respectively (%)